Homology-directed repair (HDR) is a complex DNA damage repair pathway and an attractive target of inhibition in anti-cancer therapy. To develop the most efficient inhibitors of HDR in cells, it is critical to identify compensatory sub-pathways. In this study, we describe the synthetic interaction between RAD51AP1 and RAD54, two structurally unrelated proteins that function downstream of RAD51 in HDR. We show that deletion of both RAD51AP1 and RAD54 synergistically sensitizes human cancer cell lines to treatment with a Poly(adenosine 5'-diphosphate-ribose) polymerase inhibitor, to the DNA inter-strand crosslinking agent mitomycin C, and to hydroxyurea, which stalls the progression of DNA replication. We infer that HDR-directed anti-cancer treatment modalities shall consider this within-pathway functional overlap, and we hypothesize that in cancerous cells the simultaneous inactivation of both RAD54 and RAD51AP1 will accentuate tumor kill.